Global Trigeminal Neuralgia Treatment Trends 2025, Forecast To 2034
26 Mar, 2025
What Has Been the Progress and Growth of the Trigeminal Neuralgia Treatment Market in Recent Years?
The trigeminal neuralgia treatment market has seen considerable growth due to a variety of factors.
• In recent times, the market for trigeminal neuralgia treatment has witnessed substantial growth. Projected to rise from $0.68 billion in 2024 to $0.73 billion in 2025, it boasts a compound annual growth rate (CAGR) of 7.1%.
The significant growth during the historical period can be associated with factors such as the heightened occurrence of chronic diseases, increased number of neurological disorders, rising cases of trigeminal neuralgia, escalating demand for minimally invasive therapeutic options, and a surge in the requirement for minimally invasive surgeries.
What Is The Expected Growth In The Trigeminal Neuralgia Treatment Market Size Evolve over the Forecast Period?
The trigeminal neuralgia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for trigeminal neuralgia treatment is predicted to experience substantial growth in the coming years, reaching an estimate of $0.95 billion by 2029 with a compound annual growth rate (CAGR) of 6.7%.
The expected growth during the forecast period is due to the growing awareness of trigeminal neuralgia among healthcare professionals and the public, an escalation in TN instances, an increasing elderly population, the rise in healthcare spending, and an increased diagnosis rate. Key trends anticipated during the forecast period involve the progression in neuromodulation methods, technological advancements in TENS, enhancements in medical research and technology, the adoption of minimally invasive surgical methods and the rise of digital healthcare technologies.
What Main Forces Are Fueling Expansion In The Trigeminal Neuralgia Treatment Market?
The escalating occurrence of neurological disorders is predicted to spur the expansion of the trigeminal neuralgia treatment market. Neurological disorders encompass conditions impacting the nervous system, involving the brain, spinal cord, and nerves. The growing occurrence of these disorders can be linked to a variety of causes, such as genetic susceptibility, infections, injuries, toxins, autoimmune reactions, and deterioration. Trigeminal neuralgia therapy aids patients with neurological conditions by alleviating intense facial pain, diminishing nerve irritation, improving life quality, aiding in pain management, and averting further neurological damage. For example, the European Brain Council, a non-profit organization based in Belgium, reported in April 2022 that over 600 neurological illnesses and nearly 300 psychiatric conditions plague millions worldwide, including 65 million individuals living with epilepsy. In Europe, there are 10.5 million individuals suffering from dementia, with forecasts predicting an increase to 18.7 million by 2050. Hence, the escalating occurrence of neurological disorders is anticipated to accelerate the growth of the trigeminal neuralgia treatment market.
What Are The Primary Segments In The Global Trigeminal Neuralgia Treatment Market?
The trigeminal neuralgia treatment market covered in this report is segmented –
1) By Treatment Type: Medications, Surgery, Other Treatment Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Medications: Anticonvulsants, Muscle Relaxants, Antidepressants
2) By Surgery: Microvascular Decompression Surgery, Gamma Knife Radiosurgery, Rhizotomy
3) By Other Treatment Types: Nerve Blocks, Stereotactic Radiosurgery, Physical Therapy
How Are New Trends Impacting The Size Of The Trigeminal Neuralgia Treatment Market?
Key players in the trigeminal neuralgia treatment market are concentrating their efforts on the submission of new drug (IND) applications in a bid to secure regulatory authorization and broaden their market influence. A company that develops pharmaceuticals seeks approval through an investigational new drug (IND) application to begin testing a newly developed drug on humans, with the aim of determining its safety, effectiveness, and proper dosage. For instance, Noema Pharma, a Swiss biotech company focusing on clinical stages, was granted an Investigational New Drug (IND) application by the US's Food and Drug Administration (FDA) in February 2022. The application was for LibraTN to launch a Phase 2b clincial trial of the mGluR5 inihibitor NOE-101 for trigeminal neuralgia (TN). The LibraTN study is a 24-week, multi-center, placebo-controlled trial aiming to evaluate the effectiveness and safety of NOE-101 in adults suffering from TN-associated pain, with the results expected to be released in the first half of 2024. Moreover, the Food and Drug Administration (FDA) granted fast track designation to basimglurant (NOE-101) to accelerate the drug's development and review.
Who Are the Key Players In The Trigeminal Neuralgia Treatment Market?
Major companies operating in the trigeminal neuralgia treatment market are:
• Aetna Inc.
• Thermo Fisher Scientific Inc.
• Novartis AG
• Sandoz
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.
• Lupin Limited
• Taro Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Kriya Therapeutics
• Convergence Pharmaceuticals Limited
• Noema Pharma AG
• Max Healthcare
• Initiator Pharma AS
• Coda Biotherapeutics Inc.
• Oxford Cannabinoid Technologies Holdings Plc
• NanoVibronix
• Biogen Idec
• Shanghai SIMR Biotechnology Co. Ltd.
• Capnia Inc.
What Is The Most Dominant Region In The Trigeminal Neuralgia Treatment Market?
North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.